MedTrace Logo

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

NCT05177939 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-12-01

No results posted yet for this study

Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

Conditions

  • Autoimmune Encephalitis

Interventions

DRUG

NPB-01

NPB-01 will be administered for the treatment of autoimmune encephalitis

DRUG

NPB-01-ME

NPB-01-ME will be administered for the treatment of autoimmune encephalitis

Sponsors & Collaborators

  • Nihon Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Mamoru Ota · Nihon Pharmaceutical Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2024-05-31
Completion
2024-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177939 on ClinicalTrials.gov